Scarica l'app Stockscreener
28.32
0.81%
-0.23
Dopo l'orario di chiusura:
28.30
-0.02
-0.07%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PFE Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$28.55
Aprire:
$28.5
Volume 24 ore:
30.90M
Relative Volume:
0.69
Capitalizzazione di mercato:
$161.09B
Reddito:
$62.58B
Utile/perdita netta:
$7.79B
Rapporto P/E:
20.90
EPS:
1.3551
Flusso di cassa netto:
$9.08B
1 W Prestazione:
+2.72%
1M Prestazione:
+3.89%
6M Prestazione:
+4.58%
1 anno Prestazione:
+14.66%
Intervallo 1D:
$28.22
$28.75
Intervallo di 1 settimana:
$27.02
$28.75
Portata 52W:
$20.91
$28.75
Pfizer Inc Stock (PFE) Company Profile
Nome
Pfizer Inc
Settore
Industria
Telefono
(212) 733-2323
Indirizzo
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, AZN, MRK
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
28.32 | 161.09B | 62.58B | 7.79B | 9.08B | 1.3551 |
LLY
Lilly Eli Co
|
935.58 | 835.81B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
243.04 | 585.39B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
208.84 | 369.39B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
203.49 | 315.58B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
120.87 | 298.84B | 64.93B | 18.26B | 12.36B | 7.2751 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-02 | Aggiornamento | Argus | Hold → Buy |
| 2026-02-25 | Iniziato | RBC Capital Mkts | Underperform |
| 2026-02-20 | Iniziato | Barclays | Underweight |
| 2026-02-12 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-02 | Ripresa | Citigroup | Neutral |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-25 | Ripresa | Citigroup | Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Downgrade | Argus | Buy → Hold |
| 2024-02-23 | Iniziato | Guggenheim | Buy |
| 2024-01-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-10-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-17 | Reiterato | JP Morgan | Neutral |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-06-29 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Downgrade | UBS | Buy → Neutral |
| 2023-01-17 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-12-13 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-20 | Reiterato | Cowen | Outperform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-13 | Aggiornamento | UBS | Neutral → Buy |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-05-06 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-12-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Ripresa | Goldman | Neutral |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-10-12 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-16 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-27 | Aggiornamento | Standpoint Research | Hold → Buy |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-07-30 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Ripresa | Morgan Stanley | Overweight |
| 2019-02-20 | Ripresa | Citigroup | Neutral |
| 2019-01-31 | Aggiornamento | Argus | Hold → Buy |
| 2019-01-31 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Downgrade | UBS | Buy → Neutral |
| 2018-12-11 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Mostra tutto
Pfizer Inc Borsa (PFE) Ultime notizie
A Look At Adaptive Biotechnologies (ADPT) Valuation After Q4 2025 Beat And New Pfizer Agreements - finance.yahoo.com
Raab & Moskowitz Asset Management LLC Sells 39,910 Shares of Pfizer Inc. $PFE - MarketBeat
SteelPeak Wealth LLC Grows Position in Pfizer Inc. $PFE - MarketBeat
Poland, Romania Ordered to Honor Vaccine Deal with Pfizer - Insider Monkey
Pfizer Inc. (PFE) latest press releases and corporate news - Yahoo Finance Singapore
How Pfizer’s Lyme Vaccine Trial Results Could Shape Pipeline Renewal for Pfizer (PFE) Investors - simplywall.st
Only one U.S. university ranks in the world’s top 10 in STEM. Pfizer’s CEO is calling for change - finance.yahoo.com
Pfizer Loses Bid to Dismiss Disability Bias Lawsuit - National Today
Pfizer Fails to Escape Warehouse Worker’s Disability Bias Suit - Bloomberg Law News
Ever Wonder How Medicines Get Their Names? - pfizer.com
38,600 Shares in Pfizer Inc. $PFE Acquired by Genesis Financial Group LLC - MarketBeat
Pfizer Inc. $PFE Stock Position Reduced by First Pacific Financial - MarketBeat
Aberdeen Group plc Sells 664,801 Shares of Pfizer Inc. $PFE - MarketBeat
Declaration of shares and voting rights of Valneva SE – March 2026 - GlobeNewswire Inc.
Pfizer Site Closure Puts Cost Focus And R&D Productivity In Spotlight - Yahoo Finance
Pfizer RSV vaccine offered to 3M more in England (PFE:NYSE) - Seeking Alpha
Pfizer Site Closure Tests Cost Cuts And R&D Footprint Against Valuation - simplywall.st
Pfizer price soarsForecast today02-04-2026 - Economies.com
Pfizer, BioNTech Halt Large US COVID-19 Vaccine Trial Over Slow Enrollment - BioSpace
Pfizer’s RSV Shot to Be Offered to 3 Million More in England - Bloomberg.com
Pfizer Inc. $PFE Shares Purchased by Penn Davis Mcfarland Inc. - MarketBeat
Pediatric Neuroblastoma Treatment Market Outlook 2026-2030 - GlobeNewswire
Pediatric Neuroblastoma Treatment Market Outlook 2026-2030 & 2035United Therapeutics Corporation, APEIRON Biologics, Pfizer, Bayer, and Amgen Dominate - finance.yahoo.com
PFE Stock Quote Price and Forecast - CNN
GSK plc (ADR) Stock: ViiV Healthcare Ownership Restructured as Pfizer Exits, Strengthening GSK's HIV - AD HOC NEWS
Pacer S&P 500 Quality FCF High Dividend ETF's Pfizer Inc(PFE) Holding History - GuruFocus
Pfizer and BioNTech halt U.S. COVID-19 vaccine study after recruitment struggles - The Japan Times
Why Pfizer (PFE) Outpaced the Stock Market Today - finance.yahoo.com
Leerink maintains Pfizer stock rating after vaccine ruling - Investing.com
What's Going On With Pfizer Stock Wednesday?BioNTech (NASDAQ:BNTX), Pfizer (NYSE:PFE) - Benzinga
Pfizer, BioNTech halt US trial of COVID-19 vaccine over low enrollment - Daily Sabah
Pfizer, BioNTech end U.S. COVID vaccine trial over low participation: Reuters - Seeking Alpha
Pfizer (PFE) Wins EU Court Case on Vaccine Contracts - GuruFocus
Belgian court orders Poland, Romania to buy $2.2 billion of Pfizer COVID shots - MarketScreener
Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles - MarketScreener
Belgian court orders Poland, Romania to accept $2.2B of Pfizer COVID shots - Seeking Alpha
Pfizer Inc. - Britannica
Pfizer and partner BioNTech say they will stop U.S. COVID-19 vaccine study in healthy adults ages 50 to 64 due to slow enrollment - MarketScreener
Pfizer Wins €1.9 Billion Covid Vaccine Case With Poland, Romania - Bloomberg.com
PFE Stock Trades Above 200 & 50-Day SMA for 3 Months: How to Play - TradingView
Bearish on Pfizer (PFE) as Big Dividend Fails to Mask the Growth Problem - finance.yahoo.com
Pfizer (PFE) Competes in Prostate Cancer Treatment Landscape - GuruFocus
Belgian court orders Poland, Romania to buy $2.2 billion of Pfizer COVID vaccines - Reuters
Will Pfizer’s Lyme disease gamble pay off or set the space back? - pharmavoice.com
Belgium court orders Romania to take delivery of 600 mln euros worth of Pfizer Covid vaccines - MarketScreener
Pfizer Pulls Back From South San Francisco - tradingview.com
Belgium court orders Poland to take delivery of 1.3 bln euros worth of Pfizer COVID vaccines - marketscreener.com
March Social Media Round-Up—2025 Annual Review, World’s Most Ethical Companies, and More - Pfizer
GSK, Pfizer and Shionogi finalize changes to ViiV Healthcare ownership - Investing.com
Pfizer (PFE) Valuation Check As Phase 3 Lyme Vaccine And Prostate Cancer Results Draw Focus - simplywall.st
Pfizer exits ViiV as GSK (NYSE: GSK) keeps 78.3% stake, Shionogi grows - Stock Titan
Pfizer Inc Azioni (PFE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.37%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):